Portage is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. Following proof of concept, Portage will look to sell or license the products to large pharmaceutical companies for further development and commercialization. Portage has two operating subsidiaries, portage Pharmaceuticals Limited PPL which is wholly owned by Portage and Biohaven Pharmaceutical Holding Company Limited Biohaven in which Portage holds . as at June , . PPL has successfully validated CellPorter , a novel and proprietary cell permeable peptide platform that has been shown to efficiently deliver active biologic agents into cells without disrupting the cell membrane. PPL will be advancing its lead candidate, PPL , to an Investigational New Drug IND application for the topical treatment of Dry Eye Disease and Uveitis. Biohaven is a privately held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. The Company s first drug candidate, BHV , is a novel formulation of a glutamate modulating agent, being developed under FDA b guidelines. Biohaven s second compound, BHV , is an NCE for neurodegenerative and neuropsychiatric disorders.
Quote | Portage Biotech (OTCMKTS:PTGEF)
Last: | $37.50 |
---|---|
Change Percent: | 6.99% |
Open: | $35.9885 |
Close: | $37.50 |
High: | $37.5 |
Low: | $35 |
Volume: | 6,306 |
Last Trade Date Time: | 02/24/2021 04:54:48 pm |
News | Portage Biotech (OTCMKTS:PTGEF)
-- Company to advance three clinical-stage programs in pipeline -- -- Portage has received approval and is preparing for NASDAQ listing -- Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") today annou...
New York, New York--(Newsfile Corp. - December 1, 2020) - Portage Biotech (OTC Pink: PTGEF) (CSE: PBT.U) is an emerging biotechnology company developing an immunotherapy focused pipeline to treat a broad range of cancers. Unlike most biotechs though, Portage focuses on combining its own techno...
Message Board Posts | Portage Biotech (OTCMKTS:PTGEF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Portage Biotech Company Name:
PTGEF Stock Symbol:
OTCMKTS Market:
-- Company to advance three clinical-stage programs in pipeline -- -- Portage has received approval and is preparing for NASDAQ listing -- Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") today annou...
New York, New York--(Newsfile Corp. - December 1, 2020) - Portage Biotech (OTC Pink: PTGEF) (CSE: PBT.U) is an emerging biotechnology company developing an immunotherapy focused pipeline to treat a broad range of cancers. Unlike most biotechs though, Portage focuses on combining its own techno...
Toronto, Ontario--(Newsfile Corp. - October 16, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") announces that the Company has filed its interim financial statements and related management's discussion and analysis for the three-month period ending June...